The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
3 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $5,078,680 in first-year total cost, median $1,681,128.
Most frequent study sections
- Neurological Sciences and Disorders B Study Section[NSD-B]2
- Special Emphasis Panel[ZNS1 SRB-M (03)]1
Most frequent institutions
- BECKMAN RESEARCH INSTITUTE/CITY OF HOPE1
- CHILDREN'S HOSP OF PHILADELPHIA1
- MCLEAN HOSPITAL1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2021 | A Human iPSC-based Cell Therapy for Canavan Disease1U01NS122101-01 | SHI, YANHONG | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $1,757,552 | ZNS1 |
| 2020 | Parkinsons disease scalable iPSC autologous cell therapy1U01NS109463-01A1 | HALLETT, PENELOPE JANEISACSON, OLEOSBORN, ANNA CHARLOTTA TERESIA MAGNUSONSCHUMACHER, JAMES M | MCLEAN HOSPITAL, MA | $1,640,000 | NSD |
| 2019 | Therapeutic APOE2 overexpression for early Alzheimer's disease1U01NS111671-01 | DAVIDSON, BEVERLY L. | CHILDREN'S HOSP OF PHILADELPHIA, PA | $1,681,128 | NSD |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.